Cartesian Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense in USD from 2014 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Cartesian Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2014 to 2023.
  • Cartesian Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $1.59M, a 57.9% decline year-over-year.
  • Cartesian Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $22.7M, a 108% increase year-over-year.
  • Cartesian Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $25.8M, a 130% increase from 2022.
  • Cartesian Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $11.2M, a 45% increase from 2021.
  • Cartesian Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $7.72M, a 42.4% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $25.8M +$14.6M +130% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-07
2022 $11.2M +$3.47M +45% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-07
2021 $7.72M +$2.3M +42.4% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-07
2020 $5.42M +$261K +5.06% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-02
2019 $5.16M -$553K -9.68% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-10
2018 $5.71M +$1.63M +40% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-12
2017 $4.08M +$2.03M +99% Jan 1, 2017 Dec 31, 2017 10-K 2019-03-15
2016 $2.05M +$926K +82.3% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-15
2015 $1.13M -$99K -8.09% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-15
2014 $1.22M Jan 1, 2014 Dec 31, 2014 10-K 2017-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.